Glofitamab: Bispecific CD20 CD3 Antibody in Relapsed DLBCL
Glofitamab (trade name Columvi, Roche) is a bispecific T cell activating antibody (BiTE-like format with IgG structure). The European Medicines Agency EMA granted conditional marketing approval in July 2023 for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after at least two prior lines of systemic therapy. Following Mosunetuzumab and Epcoritamab, Glofitamab is the third CD20 CD3 bispecific antibody construct in Europe and ranks among the most promising innovations in hematologic oncology therapy in recent years.
The distinctive feature is an unusual 2:1 architecture for bispecific antibodies: two CD20 binding domains on B cell lymphoma and one CD3 binding domain on T cells. This design enhances binding stability to the tumor and triggers very efficient T cell mediated tumor cell lysis. In the approval study NP30179, heavily pretreated DLBCL patients achieved an objective response rate of approximately 50 percent and complete remissions in approximately 39 percent.
Mechanism of Action
Glofitamab binds on one side via two Fab domains to the surface antigen CD20, which is expressed on nearly all mature B cells (including malignant ones as in DLBCL). On the other side, a single Fab domain binds to CD3 epsilon, a component of the T cell receptor complex on cytotoxic T lymphocytes. This physical bridge brings the T cell and tumor cell into spatial proximity.
The T cell is activated antigen-independently and releases granzymes and perforin, driving the tumor cell into apoptosis. Unlike chimeric antigen receptor T cells (CAR T), Glofitamab requires no prior apheresis and ex vivo manipulation of T cells, the medication is available as an off-the-shelf therapy immediately. This practical simplification is clinically significant because many DLBCL patients must bridge considerable wait times between relapse and CAR T availability.
Pharmacokinetically, Glofitamab is degraded primarily through nonspecific proteolysis as an antibody, with a mean half-life of approximately six to eleven days. This allows for three-weekly maintenance dosing after the initial step-up phase.
Indications
- Relapsed or refractory DLBCL after at least two systemic lines of therapy including CD20 directed therapy
- High Grade B Cell Lymphomas (HGBL): also included in the approval study
- Transformed follicular lymphoma (tFL): as a subset of highly aggressive lymphomas
- Adults who are ineligible for autologous stem cell transplantation or CAR T cell therapy or in whom these have failed
Clinical trials for first-line treatment of DLBCL and for other B cell lymphomas (follicular lymphoma, mantle cell lymphoma) are currently ongoing.
Dosage and Administration
Pretreatment: Seven days before the first Glofitamab appointment, patients receive 1,000 mg Obinutuzumab as a single dose intravenous infusion. This B cell depletion reduces tumor volume and thus the risk of Cytokine Release Syndrome (CRS).
Step-up Dosing: Day 1 of Cycle 1 receives 2.5 mg, Day 8 receives 10 mg, Day 15 receives the full dose of 30 mg. Subsequently, 30 mg intravenously every three weeks for a total of twelve cycles or until disease progression. The fixed treatment duration is an important feature compared to continuous therapies.
Premedication: Before each administration, at least during the step-up phase, methylprednisolone 100 mg intravenously, paracetamol, and an antihistamine to mitigate CRS, fever, and allergic reactions. The first two administrations occur under inpatient observation.
Adverse Effects
Very Frequently: Cytokine Release Syndrome (CRS) in approximately 64 percent, mostly Grade 1 or 2 (fever, hypotension, hypoxia, chills), rare Grade 3 or 4 courses; neutropenia, anemia, thrombocytopenia, infections, fatigue, nausea.
Frequently: Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) with confusion, aphasia, seizures, Tumor Lysis Syndrome particularly with large tumor volume, hepatitis B reactivation, severe infections including opportunistic pathogens, hypogammaglobulinemia following prolonged B cell depletion.
Important: Hepatitis B screening is mandatory before starting therapy and, if indicated, antiviral prophylaxis with Entecavir or Tenofovir. In case of CRS, Tocilizumab can be used, the clinical team must be trained in recognition and management.
Drug Interactions
- Live vaccines: contraindicated during and for at least six months after therapy completion
- Other immunosuppressive agents: additive infection risk, indication must be critically assessed
- Systemic glucocorticoids: are part of premedication; chronic high-dose therapy may dampen T cell activation and potentially reduce efficacy
- Prior treatment with CAR T cells or other bispecific antibodies: possible antigen loss phenomenon, discussion in interdisciplinary tumor board
Special Considerations
Pregnancy and Nursing: Glofitamab is contraindicated during pregnancy as antibodies cross the placental barrier and can cause B cell depletion in the fetus. Reliable contraception is required during and for at least two months after the final dose.
CRS Management: Patients must remain under inpatient observation for 24 hours after the first two step-up doses. In case of fever, hypotension, or hypoxia, clinic guidelines apply (CRS grading per ASTCT, Tocilizumab and steroids based on severity).
Infection Prophylaxis: Pneumocystis jirovecii prophylaxis (Cotrimoxazole or Pentamidine) is standard, as is antiviral prophylaxis (Acyclovir against HSV/VZV). Vaccination status should be updated before therapy.
Treatment Setting: Glofitamab may only be administered in centers with experience in the use of immunotherapies for hematologic malignancies and with access to intensive care.
You May Also Be Interested In
- Obinutuzumab, the pretreatment antibody
- Rituximab, classical monovalent anti CD20 antibody
- Teclistamab, BCMA CD3 bispecific in multiple myeloma
- Tisagenlecleucel, CAR T cell therapy in DLBCL
- Polatuzumab, antibody drug conjugate in DLBCL
Frequently Asked Questions
What is the advantage of a bispecific antibody compared to CAR T?
Glofitamab is available as an off-the-shelf medication immediately, eliminating the time-consuming apheresis and manufacturing of individual cell products. This is particularly relevant for patients with rapidly progressive lymphoma. CAR T cells can produce very long remissions; the comparison of both therapies depends on the individual patient's condition.
How dangerous is Cytokine Release Syndrome?
CRS is the most common severe adverse effect. Most cases are mild with fever, chills, and slight blood pressure drop, manageable with paracetamol, oxygen, and fluids. Severe cases with hypotension and hypoxia require Tocilizumab and intensive care. Step-up dosing and Obinutuzumab pretreatment significantly reduce the risk.
Is the therapy time-limited?
Yes. Glofitamab is given over twelve cycles, approximately nine months. This fixed treatment duration is an important difference from continuously administered therapies such as BTK inhibitors or Lenalidomide and can improve quality of life once treatment is completed.
What response rates do the studies show?
In the approval study NP30179, approximately half of heavily pretreated DLBCL patients achieved tumor shrinkage, approximately 39 percent achieved complete remission. The median duration of response had not been reached at the time of analysis. The data are considered very good for a therapy used in the third or later line.
Sources
- EMA, Columvi (Glofitamab) EPAR
- DGHO Onkopedia, Diffuse Large B Cell Lymphoma
- American Society of Hematology Publications NP30179 (Dickinson et al.)
- BfArM, Federal Institute for Drugs and Medical Devices
Legal Information and Disclaimer
The information provided on this page is for general information purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. It does not replace the advice of a licensed physician or pharmacist. Medications should always be taken only upon medical prescription or pharmacy dispensing. All information is based on published prescribing information and recognized scientific sources at the time of preparation; the current prescribing information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, accuracy, or timeliness of the information presented. In a medical emergency, call emergency number 112.